Risk of lymphoma in other rheumatoid arthritis cohorts compared with appropriate populations
| Study | Cohort details | Site | SIR | 95% CI |
|---|---|---|---|---|
| AZA, azathioprine; CI, confidence interval; IP, inflammatory polyarthritis; MTX, methotrexate; NHL, non-Hodgkin’s lymphoma; RA, rheumatoid arthritis; SIR, standardised incidence ratio; TNF, tumour necrosis factor. | ||||
| Finland, 19784 | RA | Lymphoma | 2.7 | 1.9 to 3.7 |
| UK, 198433 | RA | Haematopoietic | 8.7 | p<0.001 |
| USA, 19858 | RA | Lymphoma | 1.2 | 0.2 to 3.0 |
| UK, 198816 | RA: not treated with AZA | Lymphoproliferative malignancies | 4.8 | 0.58 to 17.2 |
| Sweden, 19933 | RA | Lymphoma | 1.98 | 1.5 to 2.6 |
| Canada, 19977 | RA | NHL | 0.55 | 0.11 to 1.6 |
| Denmark, 19965 | RA | NHL | 2.4 | 1.9 to 2.9 |
| Sweden, 20031 | RA (hospital inpatients) | Lymphoma | 2 | 1.83 to 2.17 |
| USA, 20046 | RA: treated with anti-TNF, MTX, or none at all | Lymphoma | 1.9 | 1.3 to 2.7 |
| Sweden, 20052 | Incident RA | Lymphoma | 2.0 | 1.0 to 3.5 |
| Current study (Norfolk, UK) | IP | Lymphoma | 2.34 | 1.18 to 4.24 |